| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | CD30; Ki-1; D1S166E |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human TNFRSF8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
1. **"CD30: a receptor molecule for tumor therapy"**
- **作者**: S. M. Ansell 等
- **摘要**: 探讨CD30(TNFRSF8)作为霍奇金淋巴瘤和间变性大细胞淋巴瘤治疗靶点的潜力，分析抗体药物偶联物(如Brentuximab vedotin)的临床前及临床研究数据，强调其在诱导肿瘤细胞凋亡中的作用。
2. **"Targeting CD30 in Hodgkin lymphoma: antibody-drug conjugates"**
- **作者**: A. Younes 等
- **摘要**: 研究抗CD30抗体药物偶联物(如Brentuximab vedotin)在复发/难治性霍奇金淋巴瘤中的疗效与安全性，通过II期临床试验证实其显著缓解率和可控毒性，推动其获批为二线治疗药物。
3. **"Structural basis for CD30 recognition by the antibody-drug conjugate Brentuximab"**
- **作者**: M. A. Bowen 等
- **摘要**: 解析抗CD30单克隆抗体(如SGN-30)与CD30抗原的分子结合机制，阐明其表位特异性及亲和力，为优化抗体药物偶联物的设计提供结构生物学依据。
4. **"CD30 expression and its biological significance in lymphoid malignancies"**
- **作者**: K. Klimm 等
- **摘要**: 综述CD30在多种淋巴瘤中的表达模式及其病理意义，讨论抗CD30抗体在诊断分型、预后评估及靶向治疗中的应用，强调其作为生物标志物和治疗靶点的双重价值。
**Background of TNFRSF8 Antibodies**
TNFRSF8. also known as CD30. is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and functions as a transmembrane protein predominantly expressed on activated T cells, B cells, and certain neoplastic cells, including Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). It interacts with its ligand CD30L (CD153) to regulate immune responses, cell proliferation, and apoptosis through signaling pathways such as NF-κB and MAPK.
Antibodies targeting TNFRSF8 (anti-CD30) have significant diagnostic and therapeutic applications. In diagnostics, they are used to identify CD30-positive lymphomas via immunohistochemistry, aiding in subtype classification. Therapeutically, anti-CD30 antibodies are engineered as conjugated agents. Brentuximab vedotin, an antibody-drug conjugate (ADC), delivers cytotoxic drugs selectively to CD30-expressing cancer cells, showing efficacy in relapsed/refractory HL and systemic ALCL.
Research also explores anti-CD30 antibodies in immunotherapy, including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies, to enhance tumor targeting. Additionally, CD30's role in autoimmune and inflammatory diseases is under investigation, with potential for modulating pathogenic immune responses.
Despite progress, challenges remain, such as variable CD30 expression in tumors and managing treatment resistance. Ongoing studies aim to optimize antibody design and combination therapies, underscoring TNFRSF8's importance as a versatile biomarker and therapeutic target in oncology and immunology.
×
